PATENTSCOPE will be unavailable a few hours for maintenance reason on Monday 03.02.2020 at 10:00 AM CET
Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO1989007452) IMPROVEMENTS IN OR RELATING TO ANTIBODIES
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

Claims

1. An antibody having at least one CDR (complementarity determining region) which is foreign with respect to the constant region of the antibody, said at least one foreign CDR being selected from CDRs substantially as identified in Figure 2, that is amino acid residues 31 to 35, 50 to 65 and 95 to 102 of the heavy chain as shown in Figure 2a, and amino acid residues 24 to 34, 50 to 56 and 89 to 97 of the light chain as shown in Figure 2b, the antibody being capable of binding effectively to the antigen Campath-1.

2. An antibody according to claim 1, having a heavy chain with at least one CDR selected from said CDRs
substantially as identified in Figure 2a and a light chain with at least one CDR selected from said CDRs
substantially as identified in Figure 2b.

3. An antibody according to claim 1, having a heavy chain with three CDRs substantially as identified in Figure 2a or a light chain with three CDRs substantially as
identified in Figure 2b.

4. An antibody having heavy and light chain CDRs which are foreign with respect to the constant region of the antibody, said CDRs being substantially as identified in Figure 2, that is residues 31 to 35, 50 to 65 and 95 to 102 of the heavy chain as shown in Figure 2a, and
residues 24 to 34, 50 to 56 and 89 to 97 of the light chain as shown in Figure 2b, the antibody being capable of binding -effectively to the antigen Campath-1.

5. An antibody according to claim 1, wherein the CDRs are combined with variable domain framework regions of human origin.

6. An antibody having heavy and light chain variable domains as identified in the lower lines of sequence information in Figure 2, that is residues 1 to 113 of the heavy chain and residues 1 to 108 of the light chain, the CDRs and constant region of the antibody being foreign with respect to one another, the antibody being capable of binding effectively to the antigen Campath-1.

7. An antibody having heavy and light chain variable domains as identified in the upper lines of sequence information in Figure 2, namely residues 1 to 113 of the heavy chain and residues 1 to 108 of the light chain, and that will bind effectively to the antigen Campath-1.

8. An antibody according to claim 7, having phenylalanine at residue 27 in the heavy chain in place of serine.

9. An antibody according to claim 8, having threonine at residue 30 in the heavy chain in place of serine.

10. An antibody according to claim 1, wherein the heavy and light chain constant domains are selected from
antibodies from different species type.

11. An antibody according to claim 10, wherein said different species type include rat and human.

12. An antibody according to claim 1, wherein the heavy and light chain constant domains are selected from
antibodies of different classes.

13. An antibody according to claim 12, wherein the
different antibody classes include IgG and IgM.

14. An antibody according to claim 13, wherein the heavy and light chain constant domains are of human IgGl class.

15. An antibody composition for administration to patients comprising an antibody according to claim 1 in
substantially biologically pure form together with a physiologically acceptable diluent or carrier.

16. An antibody composition according to claim 15, wherein said antibody is at least 95% (by weight) free of other biological materials.

17. An method of treating humans with cancers,
particularly ly phomas, comprising administering an antibody composition according to claim 15.

18. A method of treating humans for immunosuppression purposes, comprising administering an antibody composition according to claim 15.

19. A method of depleting lymphocytes in humans comprising administering an antibody composition according to claim 15.

20. A method of treatment according to claim 19, wherein the antibody composition is administered by intravenous infusion.

21. A method of treatment according to claim 19, wherein said intravenous infusion is administered at the rate of 5mg antibody per day for at least 10 days.